by Mark Curtis | Jan 13, 2014
. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA....
by Mark Curtis | Jan 7, 2014
. Welcome to your Update from the Clinic for the month of December. Athersys and NeoStem both confirm completion of enrollment for phase 2 studies while bluebird bio announces the first patient transplanted in its phase 1/2 study of HGB-205 in patients with...
by Holly Wobma | Jan 6, 2014
> You need only look at an old air conditioner filter to gain an enormous appreciation for our kidneys. Every day, our kidneys filter just under 200L of fluid, filled with all kinds of gnarly toxins that we’d rather not know about. Most of the time, they operate...
by Stacey Johnson | Dec 27, 2013
If you are fortunate enough to have time off over the holiday season, I’ll wager that you may spend some of that time in front of the television. Call me a Grinch, but Christmas TV programming is something that I generally avoid. If, like me, you plan on...
by Stacey Johnson | Dec 20, 2013
. With five days left to go until Christmas, are you feeling stressed about that hard-to-buy-for person on your Christmas list? Don’t despair. I have scoured the Internet on your behalf and found the perfect gift for the scientist in your life or the person who loves...
by Paul Krzyzanowski | Dec 16, 2013
> This is part three of an interview series with Michael West, CEO of BioTime. Read parts one and two. The prospects for BioTime and other companies that operate in the tissue engineering and cell therapy market are good. The industry is growing by about 18% per...
Comments